A phase I clinical trial also showed that CD40 activation enhanced anti-tumor immunity in patients with castration-resistant PCa [24], further validating A3C’s tumor-suppressive role and its potential as a target for CD40-related immunotherapy. The gene discussed is CD40; the disease is neoplasm.